📬 GYN Oncology Intelligence Digest — Week 2026-W28
RUBY Part 2 shows adding niraparib to dostarlimab maintenance improves PFS but not OS with more toxicity in advanced/recurrent endometrial cancer; new reviews address maintenance strategies, FIGO 2023 overtreatment risk, and HRD assay concordance in ovarian cancer.
⚡ TL;DR
📄 Publications
- Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy. — Risk of progression or death reduced by 40% (HR 0.60, 95% CI 0.43-0.82, p<.001) in the overall population
🐦 Twitter / 🦋 Bluesky
- EU approves tumour-agnostic trastuzumab deruxtecan, with implications for HER2 IHC testing in gynecologic tumors — Trastuzumab deruxtecan received EU approval as the first tumour-agnostic HER2-directed ADC for previously treated HER2-positive (IHC 3+) solid tumours
Full details below ↓
📄 What's Being Published
Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy. — Powell Matthew A et al., Int J Gynecol Cancer
In the RUBY Part 2 analysis, the risk of progression or death was significantly reduced by 40% (HR 0.60, 95% CI 0.43–0.82, p<.001) in the overall population and by 37% (HR 0.63, 95% CI 0.44–0.91, p=.006) in the mismatch repair-proficient/microsatellite stable population with niraparib plus dostarlimab versus control. At 36.2 months of follow-up, no overall survival benefit was observed (HR 1.2, 95% CI 0.81–1.78). Grade ≥3 treatment-related adverse events occurred in 70.7% of patients in the niraparib plus dostarlimab arm versus 37.5% in the control arm, and serious treatment-related adverse events occurred in 24.6% and 9.4%, respectively.
Clinical bottom line: Adding niraparib to dostarlimab maintenance improved PFS but produced no OS benefit and substantially more toxicity, so dostarlimab plus chemotherapy followed by dostarlimab maintenance remains the standard in advanced/recurrent endometrial cancer.
Maintenance therapy in gynecologic malignancies: Current and future state. — Widick Page C et al., Cancer
This review describes how PARP inhibitors demonstrate particularly robust results in patients with BRCA-mutated disease or other homologous recombination-deficient cancers. In endometrial and cervical cancers, immune checkpoint inhibitors combined with chemotherapy and used as maintenance thereafter have improved PFS and OS, with particular benefits noted in mismatch repair-deficient endometrial cancer and PD-L1-positive cervical cancer.
Clinical bottom line: Maintenance therapy with VEGF and PARP inhibitors in ovarian cancer and checkpoint inhibitors in endometrial and cervical cancers can improve PFS and sometimes OS, but must be weighed against added toxicity, cost, and quality-of-life impact.
FIGO 2023 staging may result in overtreatment of early-stage endometrial cancer. — Roy Allison et al., Gynecol Oncol
This analysis finds that upstaging under FIGO 2023 may result in increased treatment — including additional chemotherapy and radiation — with unclear impact on cancer outcomes. Neither the NCCN guidelines nor the literature on which treatment is based address the best treatment for patients who are upstaged.
Clinical bottom line: This analysis quantifies that FIGO 2023 upstaging of early endometrial cancer risks additional chemotherapy and radiation, so clinicians should be cautious applying literature-based recommendations to upstaged patients.
Technical evaluation of commercially available homologous recombination deficiency assays using MyChoice CDx as reference in ovarian cancer. — Yarunin Alexander et al., Gynecol Oncol
Using MyChoice CDx as reference, overall percentage agreement for HRD status ranged 76.0%–88.7%; positive percentage agreement ranged 81.6%–93.8%, and negative percentage agreement ranged 70.3%–90.4% across commercially available assays. Among simulated HRD-positive participants, mean progression-free survival hazard ratio was 0.40 at PPA of 80% and NPA of 85%, and 0.38 at PPA of 75% and NPA of 90%.
Clinical bottom line: Commercially available HRD assays showed acceptable concordance with MyChoice CDx for HRD, genomic instability, and BRCA mutation detection, supporting their potential clinical utility for treatment selection in ovarian cancer.
🗣️ What People Were Discussing This Week
How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).
EU approves tumour-agnostic trastuzumab deruxtecan, with implications for HER2 IHC testing in gynecologic tumors
Trastuzumab deruxtecan received EU approval as the first tumour-agnostic HER2-directed antibody-drug conjugate for previously treated, unresectable or metastatic HER2-positive (IHC 3+) solid tumours without satisfactory options. Because the approval is based on HER2 IHC 3+, which is not captured by NGS, oncologists will need to proactively request HER2 IHC for patients potentially eligible for trastuzumab deruxtecan — including those with HER2-positive gynecologic tumors. The central question for specialists is how HER2 IHC testing should be integrated into the standard workup for gynecologic tumors now that this tumour-agnostic indication is available in Europe.
Discussed by: @OncoAlert, @EladSharonMD
🔥 Top Ranked Tweets
OncoAlert @OncoAlert
NEWS FROM INDUSTRY/ DESTINY UPDATE (#LungCancer #CRC )
Source AstraZeneca
https://t.co/zB6Smwcrcc
AstraZeneca and Daiichi Sankyo’s trastuzumab deruxtecan 🧪 has received EU 🇪🇺 approval as the first tumour-agnostic 🧬 HER2-directed antibody-drug conjugate for previously treated, unresectable or metastatic HER2-positive (IHC 3+) solid tumours without satisfactory options. The decision is based on Phase II DESTINY trials showing meaningful responses across tumour types, including pancreatic, ovarian, lung and colorectal cancers, highlighting the expanding role of biomarker-driven precision oncology.
Pinging 🚨 Faculty
@ChristianRolfo @GlopesMd @NarjustFlorezMD @StephenVLiu @bmassutis @Tony_Calles @s_couraud @marinagarassino @peters_solange @UmbertoMalapel1 @g_mountzios @CharuAggarwalMD @christine_lovly @BairdAM @barlesi @jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat @alexdrilon @JordiRemon @DrJNaidoo @caliraf @MartinReck2 @Latinamd @JulienMazieres @TerriConneran
@pashtoonkasi @CathyEngMD @marklewismd @AndresC27622123 @manjuggm @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen
#OncoAlertAF
@nataliagandur @realbowtiedoc @FernandoOnco @ElisaAgostinett @to_be_elizabeth @BRicciutiMD @HHorinouchi @UOzkerim @p_ciracimd @MarioBalsaMD @scocmem @AmandaNizamMD @DrVilmaPBarcia @DraMartinezLago
🔖 3 ❤️ 27 🔁 15 👁 5,050
Elad Sharon @EladSharonMD
RT @PTarantinoMD: Finally histology agnostic T-DXd reaches Europe!
Key fact to remember: the approval is based on HER2 IHC 3+, which is not captured by NGS — thus, it will be critical to proactively request HER2 IHC for patients potentially eligible for T-DXd (eg HER2+ GYN tumors, mUC, mCRC…)
🔖 4 ❤️ 48 🔁 14 👁 7,370
OncoAlert @OncoAlert
RT @OncoAlert: NEWS FROM INDUSTRY/ DESTINY UPDATE (#LungCancer #CRC )
Source AstraZeneca
https://t.co/zB6Smwcrcc
AstraZeneca and Daiichi Sankyo’s trastuzumab deruxtecan 🧪 has received EU 🇪🇺 approval as the first tumour-agnostic 🧬 HER2-directed antibody-drug conjugate for previously treated, unresectable or metastatic HER2-positive (IHC 3+) solid tumours without satisfactory options. The decision is based on Phase II DESTINY trials showing meaningful responses across tumour types, including pancreatic, ovarian, lung and colorectal cancers, highlighting the expanding role of biomarker-driven precision oncology.
Pinging 🚨 Faculty
@ChristianRolfo @GlopesMd @NarjustFlorezMD @StephenVLiu @bmassutis @Tony_Calles @s_couraud @marinagarassino @peters_solange @UmbertoMalapel1 @g_mountzios @CharuAggarwalMD @christine_lovly @BairdAM @barlesi @jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat @alexdrilon @JordiRemon @DrJNaidoo @caliraf @MartinReck2 @Latinamd @JulienMazieres @TerriConneran
@pashtoonkasi @CathyEngMD @marklewismd @AndresC27622123 @manjuggm @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen
#OncoAlertAF
@nataliagandur @realbowtiedoc @FernandoOnco @ElisaAgostinett @to_be_elizabeth @BRicciutiMD @HHorinouchi @UOzkerim @p_ciracimd @MarioBalsaMD @scocmem @AmandaNizamMD @DrVilmaPBarcia @DraMartinezLago
🔖 3 ❤️ 27 🔁 15 👁 5,050
Sanjay Popat @DrSanjayPopat
RT @OncoAlert: NEWS FROM INDUSTRY/ DESTINY UPDATE (#LungCancer #CRC )
Source AstraZeneca
https://t.co/zB6Smwcrcc
AstraZeneca and Daiichi Sankyo’s trastuzumab deruxtecan 🧪 has received EU 🇪🇺 approval as the first tumour-agnostic 🧬 HER2-directed antibody-drug conjugate for previously treated, unresectable or metastatic HER2-positive (IHC 3+) solid tumours without satisfactory options. The decision is based on Phase II DESTINY trials showing meaningful responses across tumour types, including pancreatic, ovarian, lung and colorectal cancers, highlighting the expanding role of biomarker-driven precision oncology.
Pinging 🚨 Faculty
@ChristianRolfo @GlopesMd @NarjustFlorezMD @StephenVLiu @bmassutis @Tony_Calles @s_couraud @marinagarassino @peters_solange @UmbertoMalapel1 @g_mountzios @CharuAggarwalMD @christine_lovly @BairdAM @barlesi @jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat @alexdrilon @JordiRemon @DrJNaidoo @caliraf @MartinReck2 @Latinamd @JulienMazieres @TerriConneran
@pashtoonkasi @CathyEngMD @marklewismd @AndresC27622123 @manjuggm @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen
#OncoAlertAF
@nataliagandur @realbowtiedoc @FernandoOnco @ElisaAgostinett @to_be_elizabeth @BRicciutiMD @HHorinouchi @UOzkerim @p_ciracimd @MarioBalsaMD @scocmem @AmandaNizamMD @DrVilmaPBarcia @DraMartinezLago
🔖 3 ❤️ 27 🔁 15 👁 5,050
Nicholas Hornstein @GIMedOnc
Great newsletter from @OncoAlert highlighting last weeks major advances in oncology (not included is ongoing coverage of #ASCOGI26 which you can find on their feed)
[Quoting @OncoAlert: The OncoAlert Newsletter June 25- July 1, ,2026
REGISTER TO GET IT👉 https://t.co/mrihkMKWad or https://t.co/R13F8zzj1Y
🔥 Highlights include:
🔹 Industry Update:
🇪🇺 EU approval of trastuzumab deruxtecan as the first tumour-agnostic HER2-directed ADC for previously treated HER2-positive solid tumors — expanding the impact of biomarker-driven oncology.
#ADC #PrecisionOncology #HER2
🔹 Lung Cancer:
🫁 TP53 gain-of-function mutations linked to early osimertinib resistance in EGFR-mutant NSCLC
🫁 Identifying patients at risk for early failure with dual immunotherapy in metastatic NSCLC
🔹 GU Cancers:
🧬 9+ year follow-up confirms durable survival benefit of nivolumab + ipilimumab in advanced RCC
🧬 PSMA PET/CT-guided MDT associated with improved outcomes in oligometastatic CRPC
🔹 Breast Cancer:
🎗️ iSBRT + immunotherapy strategies in ER+/HER2− disease
🎗️ Pregnancy-associated breast cancer outcomes and the role of tumor biology
🔹 GI Cancers:
🎯 New ESTRO recommendations for rectal cancer reirradiation
🎯 Real-world data on adjuvant chemotherapy in biliary tract cancers
🔹 Cancer & Innovation:
🤖 AI decision support in hematologic malignancies
🤖 Machine learning models for cervical cancer risk stratification
🧬 The evolving role of intratumoral therapies in melanoma
📚 Stay updated with the latest evidence shaping clinical practice.
@matteolambe
@aftimosp
@E_de_Azambuja
@DrSGraff
@ErikaHamilton9
@double_whammied
@maryam_lustberg
@raalbany
@hoperugo
@stolaney1
@LoiSher
@JaniceTNBCmets
@montypal
@DrDanielHeng
@apolo_andrea
@DrChoueiri
@PGrivasMDPhD
@TiansterZhang
@neerajaiims
@amerseburger
@sonpavde
@drenriquegrande
@tompowles1
@cdanicas
@nataliagandur
@realbowtiedoc
@Onco_Cifu88
@scocmem
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@realbowtiedoc
@Erman_Akkus
@MarioBalsaMD
@DrMirallas
@GIMedOnc
@UOzkerim
@DrRishabhOnco
@Onco_Cifu88
@PaulJiL
@DaisukeKotani
@DraMartinezLago
@p_ciracimd
@BenWestphalen
@CentralParkWMD
@graokane
@amandaNizamMD
@DrVilmaPBarcia]
🔖 1 ❤️ 11 🔁 4 👁 2,791
JCO Oncology Advances @JCOOA_ASCO
Patterns of Care and Outcomes of Neoadjuvant Chemotherapy or Primary Surgery in Stage III-IV Ovarian Cancer – An Ancillary Study of GOG 262.
Read the full article. https://t.co/4YvxVJ2DL3
#OvarianCancer
🔖 1 ❤️ 3 🔁 2 👁 179
Genes & Diseases Journal @GenesNDiseases
This review summarizes mechanisms of #PlatinumResistance in #OvarianCancer —including genomic, epigenetic, metabolic, and TME factors—and highlights promising strategies advancing treatment of platinum‑resistant ovarian cancer. @centralsouth_u
#OpenAccess: https://t.co/pbvW3810rN https://t.co/3JKKERybcZ
🔖 1 ❤️ 3 🔁 0 👁 81
@GynOncJnls @gynoncjnls
As we close out #uterinecancer awareness month #UCAM, we would like to highlight the @SGO_org's evidence based review and recommendations for endometrial cancer published in Gynecologic Oncology journal.
1️⃣ In part one of this review, the authors highlight the increasing incidence and mortality of endometrial cancer, disproportionately affecting women of color.
🩸 Prompt assessment of postmenopausal bleeding leads to early detection of endometrial cancer.
🧐 This review highlights how to best incorporate elements of the 2009 and 2023 @FIGO_HQ staging strategies
🔬 Finally, this article reviews the research behind adjuvant therapy strategies for high risk #endometrialcancer
#gynecologiconcology #gynonc
🔖 0 ❤️ 3 🔁 1 👁 295
OncLive.com @OncLive
WATCH 👀: @omalleygynonc of @OSUCCC_James discusses how ADCs have redefined the treatment paradigm in platinum-resistant ovarian cancer.
See the whole video here ➡️: https://t.co/9LgedRlc8T
#ovca #oncology
🔖 0 ❤️ 2 🔁 1 👁 468
Hathal Haddad @Radiooncology
🎗️ 15 Days Until #BrachytherapyAwarenessDay
💗 Brachytherapy for #EndometrialCancer
The PORTEC-4a trial moves us toward truly personalized adjuvant treatment.
📊 Key findings:
✅ 564 patients
✅ 46% safely avoided adjuvant treatment
✅ 5-year vaginal recurrence:
• Molecular-guided: 4.5%
• Standard brachytherapy: 1.6%
✅ Non-inferiority achieved (p=0.005)
✅ No treatment-related deaths
🧬 Molecular profile guides treatment:
🟢 Observation
🟣 Vaginal brachytherapy
🔴 Pelvic EBRT
❤️ Brachytherapy saves lives.
#PORTEC4a #Brachytherapy #Interventional_Radiotherapy #RadiationOncology #PrecisionMedicine #ThisIsBrachytherapy
🔖 0 ❤️ 1 🔁 0 👁 23
Prepared by Rafael Santana-Davila, M.D. Questions or feedback? Just reply to this email.
Disclaimer: This digest is AI-generated. Content may contain errors -- always verify with original sources.
Know a colleague who would find this useful? Just forward them this email.